Management and Treatment of Recurrent Epithelial Ovarian Cancer

被引：45

作者：

Armbruster, Shannon ^{[1
]}

Coleman, Robert L. ^{[1
]}

Rauh-Hain, Jose Alejandro ^{[1
,2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Unit 1362, 1155 Herman Pressler, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Hlth Serv Res, Unit 1444, 1515 Holcombe Blvd,POB 301402, Houston, TX 77230 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2018年 / 32卷 / 06期

关键词：

Ovarian cancer; Recurrence; PARP; Immunotherapy; Chemotherapy; Secondary cytoreduction; PLATINUM-RESISTANT OVARIAN; PEGYLATED LIPOSOMAL DOXORUBICIN; SECONDARY CYTOREDUCTIVE SURGERY; CONTROLLED PHASE-III; DOUBLE-BLIND; OPEN-LABEL; MAINTENANCE THERAPY; PRIMARY PERITONEAL; TUMOR ANGIOGENESIS; ANTITUMOR-ACTIVITY;

D O I：

10.1016/j.hoc.2018.07.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Most women with advanced epithelial ovarian cancer will experience many episodes of recurrent disease with progressively shorter disease-free intervals. For women whose disease continues to respond to platinum based drugs, the disease can often be controlled for 5 years or more. Enormous progress has been made in the management of this disease, and new targeted treatments such as antiangiogenic drugs, poly(adenosine diphosphate-ribose) polymerase inhibitors, and immune checkpoint inhibitors offer potential for improved survival. A variety of combination strategies are being evaluated to leverage these agents. The role of secondary cytoreduction remains a topic of active investigation.

引用

页码：965 / +

页数：19

共 70 条

[11] Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer [J].

Bolton, Kelly L. ;

Chenevix-Trench, Georgia ;

Goh, Cindy ;

Sadetzki, Siegal ;

Ramus, Susan J. ;

Karlan, Beth Y. ;

Lambrechts, Diether ;

Despierre, Evelyn ;

Barrowdale, Daniel ;

McGuffog, Lesley ;

Healey, Sue ;

Easton, Douglas F. ;

Sinilnikova, Olga ;

Benitez, Javier ;

Garcia, Maria J. ;

Neuhausen, Susan ;

Gail, Mitchell H. ;

Hartge, Patricia ;

Peock, Susan ;

Frost, Debra ;

Evans, Gareth ;

Eeles, Rosalind ;

Godwin, Andrew K. ;

Daly, Mary B. ;

Kwong, Ava ;

Ma, Edmond S. K. ;

Lazaro, Conxi ;

Blanco, Ignacio ;

Montagna, Marco ;

D'Andrea, Emma ;

Nicoletto, Maria Ornella ;

Johnatty, Sharon E. ;

Krueger, Susanne ;

Jensen, Allan ;

Hogdall, Estrid ;

Goode, Ellen L. ;

Fridley, Brooke L. ;

Loud, Jennifer T. ;

Greene, Mark H. ;

Mai, Phuong L. ;

Chetrit, Angela ;

Lubin, Flora ;

Hirsh-Yechezkel, Galit ;

Glendon, Gord ;

Andrulis, Irene L. ;

Toland, Amanda E. ;

Senter, Leigha ;

Gore, Martin E. ;

Gourley, Charlie ;

Michie, Caroline O. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (04) :382-390

[12] Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis [J].

Bristow, Robert E. ;

Puri, Isha ;

Chi, Dennis S. .

GYNECOLOGIC ONCOLOGY, 2009, 112 (01) :265-274

[13] Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Coleman, Robert L. ;

Oza, Amit M. ;

Lorusso, Domenico ;

Aghajanian, Carol ;

Oaknin, Ana ;

Dean, Andrew ;

Colombo, Nicoletta ;

Weberpals, Johanne, I ;

Clamp, Andrew ;

Scambia, Giovanni ;

Leary, Alexandra ;

Holloway, Robert W. ;

Amenedo Gancedo, Margarita ;

Fong, Peter C. ;

Goh, Jeffrey C. ;

O'Malley, David M. ;

Armstrong, Deborah K. ;

Garcia-Donas, Jesus ;

Swisher, Elizabeth M. ;

Floquet, Anne ;

Konecny, Gottfried E. ;

McNeish, lain A. ;

Scott, Clare L. ;

Cameron, Terri ;

Maloney, Lara ;

Isaacson, Jeff ;

Goble, Sandra ;

Grace, Caroline ;

Harding, Thomas C. ;

Raponi, Mitch ;

Sun, James ;

Lin, Kevin K. ;

Giordano, Heidi ;

Ledermann, Jonathan A. .

LANCET, 2017, 390 (10106) :1949-1961

[14] Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial [J].

Coleman, Robert L. ;

Brady, Mark F. ;

Herzog, Thomas J. ;

Sabbatini, Paul ;

Armstrong, Deborah K. ;

Walker, Joan L. ;

Kim, Byoung-Gie ;

Fujiwara, Keiichi ;

Tewari, Krishnansu S. ;

O'Malley, David M. ;

Davidson, Susan A. ;

Rubin, Stephen C. ;

DiSilvestro, Paul ;

Basen-Engquist, Karen ;

Huang, Helen ;

Chan, John K. ;

Spirtos, Nick M. ;

Ashfaq, Raheela ;

Mannel, Robert S. .

LANCET ONCOLOGY, 2017, 18 (06) :779-791

[15] Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity. [J].

Disis, Mary L. ;

Patel, Manish R. ;

Pant, Shubham ;

Hamilton, Erika Paige ;

Lockhart, Albert C. ;

Kelly, Karen ;

Beck, J. Thaddeus ;

Gordon, Michael S. ;

Weiss, Glen J. ;

Taylor, Matthew H. ;

Chaves, Jorge ;

Mita, Alain C. ;

Chin, Kevin M. ;

von Heydebreck, Anja ;

Cuillerot, Jean-Marie ;

Gulley, James L. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[16] Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20 [J].

Du Bois, Andreas ;

Vergote, Ignace ;

Ferron, Gwenael ;

Reuss, Alexander ;

Meier, Werner ;

Greggi, Stefano ;

Jensen, Pernille Tina ;

Selle, Frededric ;

Guyon, Frederic ;

Pomel, Christophe ;

Lecuru, Fabrice ;

Zang, Rongyu ;

Avall-Lundqvist, Elisabeth ;

Kim, Jae Weon ;

Ponce, Jordi ;

Raspagliesi, Francesco ;

Ghaem-Maghami, Sadaf ;

Reinthaller, Alexander ;

Harter, Philipp ;

Sehouli, Jalid .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[17] Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer [J].

du Bois, Andreas ;

Floquet, Anne ;

Kim, Jae-Weon ;

Rau, Joern ;

del Campo, Josep M. ;

Friedlander, Michael ;

Pignata, Sandro ;

Fujiwara, Keiichi ;

Vergote, Ignace ;

Colombo, Nicoletta ;

Mirza, Mansoor R. ;

Monk, Bradley J. ;

Kimmig, Rainer ;

Ray-Coquard, Isabelle ;

Zang, Rongyu ;

Diaz-Padilla, Ivan ;

Baumann, Klaus H. ;

Mouret-Reynier, Marie-Ange ;

Kim, Jae-Hoon ;

Kurzeder, Christian ;

Lesoin, Anne ;

Vasey, Paul ;

Marth, Christian ;

Canzler, Ulrich ;

Scambia, Giovanni ;

Shimada, Muneaki ;

Calvert, Paula ;

Pujade-Lauraine, Eric ;

Kim, Byoung-Gie ;

Herzog, Thomas J. ;

Mitrica, Ionel ;

Schade-Brittinger, Carmen ;

Wang, Qiong ;

Crescenzo, Rocco ;

Harter, Philipp .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (30) :3374-U205

[18] PARP inhibitors in ovarian cancer: evidence, experience and clinical potential [J].

Evans, Tarra ;

Matulonis, Ursula .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (04) :253-267

[19] Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL). [J].

Fowler, Nathan Hale ;

Coleman, Morton ;

Stevens, Don A. ;

Smith, Sonali M. ;

Venugopal, Parameswaran ;

Martin, Peter ;

Phillips, Tycel Jovelle ;

Agajanian, Richy ;

Stephens, Deborah Marie ;

Izumi, Raquel ;

Cheung, Jean ;

Slatter, J. Greg ;

Yin, Ming ;

Hiremath, Minoti ;

Hunder, Naomi N. H. ;

Christian, Beth .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[20] A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer [J].

Friedlander, Michael ;

Hancock, Kenneth C. ;

Rischin, Danny ;

Messing, Mark J. ;

Stringer, Claude A. ;

Matthys, Gemma M. ;

Ma, Bo ;

Hodge, Jeffrey P. ;

Lager, Joanne J. .

GYNECOLOGIC ONCOLOGY, 2010, 119 (01) :32-37

← 1 2 3 4 5 6 7 →